Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database

View ORCID ProfileMansour Tobaiqy, View ORCID ProfileKatie MacLure, View ORCID ProfileHajer Elkout, View ORCID ProfileDerek Stewart
doi: https://doi.org/10.1101/2021.09.12.21263462
Mansour Tobaiqy
1Department of Pharmacology, College of Medicine, University of Jeddah, PO Box 45311, Jeddah 21512, Kingdom of Saudi Arabia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mansour Tobaiqy
  • For correspondence: mtobaiqy@uj.edu.sa mtobaiqy@uj.edu.sa
Katie MacLure
2Independent Research Consultant, Aberdeen, UK AB32 6RU;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katie MacLure
  • For correspondence: katiemaclure@outlook.com
Hajer Elkout
3Department of Family and Community Medicine, Medical Faculty, University of Tripoli, Tripoli 13275, Libya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hajer Elkout
Derek Stewart
4College of Pharmacy, QU Health, Qatar University, Doha, Qatar, P.O. Box 2713
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Derek Stewart
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Background Vaccination against COVID-19 is the cornerstone to control and mitigate the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the Oxford-AstraZeneca vaccine has received much of the attention, the other vaccines should not go unchallenged. This study aimed to determine the frequency of reported thrombotic adverse events and clinical outcomes for these three COVID-19 vaccines, namely, Moderna, Pfizer and Oxford-AstraZeneca

Methods A retrospective descriptive analysis was conducted of spontaneous reports for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines submitted to the EudraVigilance database in the period from 17 February to 14 June 2021.

Findings There were 729,496 adverse events for the three vaccines, of which 3,420 were thrombotic, mainly Oxford-AstraZeneca (n=1,988, 58·1%) followed by Pfizer (n=1,096, 32·0%) and Moderna (n=336, 9·8%). As serious adverse events, there were 705 reports of pulmonary embolism for the three vaccines, of which 130 reports (18·4%) were for Moderna, 226 reports (32·1%) for Pfizer and 349 (49·5%) for Oxford-AstraZeneca vaccines. The occurrence of pulmonary embolism is significantly associated with a fatal outcome (P=<0·001). Sixty-three fatalities were recorded (63/3420, 1.8%), of which Moderna (n=6), Pfizer (n=25) and Oxford-AstraZeneca (n=32).

Interpretation Thrombotic adverse events reported for the three vaccines remains extremely rare with multiple causative factors reported elsewhere as precipitating these events. Practicing vigilance and proper clinical management for the affected vaccines, as well as continuing to report adverse events, are essential.

Funding No funding was sought for this study.

Evidence before this study During the first quarter of 2021, several European countries suspended the use of the Oxford–AstraZeneca vaccine amid reports of blood clot events and the death of a vaccinated person. This was followed by several reports of fatalities related to pulmonary embolism and other thrombotic events including thrombocytopenia which has been referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT). The European Medicines Agency on 18 March 2021 concluded that the Oxford– AstraZeneca vaccine was safe, effective and the benefits outweighed the risks.

Added value of this study This study investigated the occurrence of thrombotic adverse events and their clinical outcomes of the three approved and most used COVID-19 vaccines namely Moderna, Pfizer and Oxford-AstraZeneca, using one of the largest spontaneous adverse events databases, namely EudraVigilance. Out of 729,496 adverse events reported for the three vaccines in the study period, only 3420 (0.47%) potential thrombotic adverse events were reported, the majority associated with Oxford-AstraZeneca (n=1,988, 58.1%).

Implications of all the available evidence More than 4·89 billion doses of different COVID-19 vaccines have been administered across the globe.

Despite thrombotic adverse events reported for the three vaccines in focus for this study - Moderna, Pfizer and Oxford-AstraZeneca - being extremely rare, so continuing to report adverse events is essential. On the basis of scientific evidence showing that benefit outweighs risk, people continue to be urged to accept the vaccination when offered.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding was received for this study

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not required for review of existing data

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The dataset is in the public domain

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 22, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database
Mansour Tobaiqy, Katie MacLure, Hajer Elkout, Derek Stewart
medRxiv 2021.09.12.21263462; doi: https://doi.org/10.1101/2021.09.12.21263462
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database
Mansour Tobaiqy, Katie MacLure, Hajer Elkout, Derek Stewart
medRxiv 2021.09.12.21263462; doi: https://doi.org/10.1101/2021.09.12.21263462

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1227)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (528)
  • Epidemiology (10001)
  • Forensic Medicine (5)
  • Gastroenterology (497)
  • Genetic and Genomic Medicine (2443)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1635)
  • Health Policy (751)
  • Health Systems and Quality Improvement (633)
  • Hematology (247)
  • HIV/AIDS (530)
  • Infectious Diseases (except HIV/AIDS) (11855)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (251)
  • Medical Ethics (74)
  • Nephrology (267)
  • Neurology (2272)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (451)
  • Occupational and Environmental Health (532)
  • Oncology (1244)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (281)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4823)
  • Radiology and Imaging (833)
  • Rehabilitation Medicine and Physical Therapy (488)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (124)
  • Urology (99)